Sano is developing a low cost, Point of Care diagnostic platform to early detect and intervene in at least 6 different diseases affecting human and vet populations. Their first focus is human chronic wounds, such as diabetic foot ulcers and venous leg ulcers, personalizing treatment to promote faster healing and avoid over $3B in treatment costs from trial and error and prolonged chronicity. They have tested their proprietary chemistry, have prototypes designed, and soon will start clinical trials and submit for regulatory clearance. "Low Cost" means that they not only anticipate faster adoption in the developed world, but also that their solution is truly a global solution, not one reserved for wealthy nations alone as obesity, diabetes, and aging population are trends affecting nearly every nation and sharply increase the incidence of chronic wounds.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Sano or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.